期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
多功能纳米载体靶向传输Survivin siRNA抑制肝细胞癌增殖 被引量:1
1
作者 彭焘 胡越 +3 位作者 李名安 黄明声 姜在波 吴春 《中山大学学报(医学版)》 CAS CSCD 北大核心 2019年第6期851-856,共6页
【目的】研究RGD修饰、MRI可视的纳米载体(RGD-PEG-g-PEI-SPION)靶向传输Survivin siRNA至肝细胞癌抑制裸鼠肝癌生长的作用;探讨RGD-PEG-g-PEI-SPION对裸鼠肝癌的MRI显像功能。【方法】经皮下注射Bel-7402细胞构建裸鼠皮下荷瘤模型;经... 【目的】研究RGD修饰、MRI可视的纳米载体(RGD-PEG-g-PEI-SPION)靶向传输Survivin siRNA至肝细胞癌抑制裸鼠肝癌生长的作用;探讨RGD-PEG-g-PEI-SPION对裸鼠肝癌的MRI显像功能。【方法】经皮下注射Bel-7402细胞构建裸鼠皮下荷瘤模型;经肿瘤生长抑制实验、肿瘤组织HE染色、免疫组织化学染色和肿瘤组织细胞凋亡试验评估RGD-PEG-g-PEI-SPION靶向传输Survivin siRNA对裸鼠肝癌的治疗功能;利用MRI成像分析RGD-PEG-g-PEI-SPION对肝细胞癌的靶向显像功能。【结果】裸鼠皮下荷瘤模型成功建立并经裸鼠尾静脉首次注射25 d后,RGD-PEG-g-PEI-SPION/siRNA、PEG-g-PEI-SPION/siRNA、RGD-PEG-g-PEI-SPION/siNC、PEG-g-PEI-SPION/siNC和PBS溶液裸鼠的皮下移植瘤体积分别为:59±8、156±7、202±7、212±9和220±8(mm3),肿瘤组织学检查显示RGD-PEG-g-PEI-SPION/siRNA实验组肿瘤坏死范围最广,Survivin蛋白表达量最低,凋亡的肿瘤细胞数量明显增多;在尾静脉注射RGD-PEG-g-PEI-SPION载体、PEG-g-PEI-SPION载体3 h后,较载体注射前皮下移植瘤的标准化MRI信号强度分别下降为原来的(51.6±4.3)%和(88.5±3.2)%。【结论】RGD-PEG-g-PEI-SPION靶向传输Survivin siRNA至肝细胞癌,促进肿瘤细胞凋亡,抑制肿瘤生长,取得了较好的抗肿瘤疗效;RGD-PEG-g-PEI-SPION对裸鼠肝癌组织具备良好的靶向MRI显像功能。 展开更多
关键词 肝细胞癌 纳米载体 SIRNA 磁共振成像
下载PDF
Hepatic artery complications after orthotopic liver transplantation: interventional treatment or retransplantation? 被引量:9
2
作者 YANG Yang LI Hua +16 位作者 FU Bin-sheng ZHANG Qi ZHANG Ying-cai LU Ming-qiang CAI Chang-jie XU Chi WANG Gen-shu YI Shu-hong ZHANG Jian ZHANG Jun-feng YI Hui-min jiang Nan jiang Hua ZHU Kang-shun jiang zai-bo SHAN Hong CHEN Gui-hua 《Chinese Medical Journal》 SCIE CAS CSCD 2008年第20期1997-2000,共4页
Background The main therapeutic treatments for hepatic artery complications after orthotopic liver transplantation (OLT) include thrombolysis, percutaneous transluminal angioplasty, stent placement, and liver retran... Background The main therapeutic treatments for hepatic artery complications after orthotopic liver transplantation (OLT) include thrombolysis, percutaneous transluminal angioplasty, stent placement, and liver retransplantation. The prognosis of hepatic artery complications after OLT is not only related to the type, extent, and timing but also closely associated with the selection and timing of the therapeutic methods. However, there is no consensus of opinion regarding the treatment of these complications. The aim of this study was to determine optimal treatment for hepatic artery complications after OLT. Methods The clinical data of 25 patients diagnosed with hepatic artery thrombosis (HAT) and hepatic artery stenosis (HAS) between October 2003 and March 2007 were retrospectively reviewed. Treatments included liver retransplantation and interventions which contain thrombolysis, percutaneous transluminal angioplasty and stent placement. Results Among five patients with HAT, 3 were treated with thrombolysis. One recovered, one died after thrombolysis and another one died of multi-organ failure after retransplantation because of recurrent HAT. The remaining 2 patients underwent successful retransplantation and have survived after that. Among 12 patients presented with HAS within 1 month postoperatively, 2 patients underwent retransplantation due to irreversible liver failure and another 10 patients were treated with interventions. The liver function failed to improve in 3 patients and retransplantations were performed in 4 patients after stent placement because of ischemic cholangitis. Among 6 patients undergoing liver retransplantations, two died of intracranial hemorrhage and infection respectively. Eight patients presented with HAS after 1 month postoperatively, 5 patients were treated with interventional management and recovered after stent placement. Among another 3 patients presented with HAS, 2 patients’ liver function was stable and one patient received late liver retransplantation due to ischemic bile duct lesion. Conclusions Individualized therapeutic regimens should be adopted in treating hepatic artery complications after OLT, according to postoperative periods, types and whether ischemic bile duct lesion exists or not. Liver retransplantation is the best treatment for patients with hepatic artery thrombosis. Interventional treatments of late HAS without irreversible liver failure or bile duct ischemia are appropriate, whereas retransplantation is recommended for early HAS. 展开更多
关键词 liver transplantation hepatic artery thrombosis hepatic artery stenosis radiology interventional RETRANSPLANTATION
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部